In addition, based on the synergistic activities of IL-17 and TNF-α, an anti-TNF-α/IL-17 bispecific neutralizing antibody (ABT-122, Abbott) is being tested in phase I in RA (Abbott website and [36]). The gene discussed is TNF; the disease is rheumatoid arthritis.